Active, not recruitingPHASE1, PHASE2NCT04180371
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
Studying Malignant non-epithelial tumor of ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- BicycleTx Limited
- Principal Investigator
- Meredith McKean, MD, MPHSarah Cannon and HCA Research Institute
- Intervention
- BT5528(drug)
- Enrollment
- 288 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2027
Study locations (28)
- California Cancer Associates for Research and Excellence, Inc., Encinitas, California, United States
- University of California - Irvine Medical Center, Orange, California, United States
- Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
- Florida Cancer Specialists, Sarasota, Florida, United States
- Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
- Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Stephenson Cancer Center (Oklahoma University), Oklahoma City, Oklahoma, United States
- Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
- Sarah Cannon and HCA Research Institute, Nashville, Tennessee, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- Virginia Cancer Specialists, Fairfax, Virginia, United States
- Institut Jules Bordet, Brussels, Belgium
- Cliniques Universitaires Saint-Luc, Brussels, Belgium
- Antwerp University Hospital (UZA), Edegem, Belgium
- +13 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04180371 on ClinicalTrials.govOther trials for Malignant non-epithelial tumor of ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07189871177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsRadiopharm Theranostics, Ltd
- RECRUITINGPHASE1NCT07216105FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid TumorsFate Therapeutics
- RECRUITINGPHASE1NCT06238479A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsEli Lilly and Company
- ACTIVE NOT RECRUITINGPHASE2NCT06169124Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell TumorsNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT05872204Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian CancerUniversitaire Ziekenhuizen KU Leuven
- RECRUITINGPHASE2NCT04644289WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOCAGO Research GmbH
See all trials for Malignant non-epithelial tumor of ovary →